We wanted to flag a recent poster from an academic retrospective analysis linked HERE that could dampen uptake of Vyxeos, Jazz’s AML drug with ~ $380mm in 2026 consensus estimates, vs generic High-dose Cytarabine treatment regimens (HiDAC) in secondary AML where its currently approved. Please note, the poster will formally presented at ASH on Sunday December 8th at 6pm (abstract # 2639)...although we noticed one of the study authors tweeted the poster recently
Search Coverage List, Models & Reports
Search Results1-10 out of 16
Axsome’s AXS-12, an oral previously failed antidepressant that we felt could be a threat to Xyrem’s narcolepsy franchise (see our preview note below), hit its phII primary endpoint (n=21) by showing a stat sig reduction in # of cataplexy attacks… call at 8AM EST (844) 698-4029
Jazz reported what at 1st glance seems like a very positive Q3 – topline revenues beat by $12mm, EPS came out well ahead as well ($4.10 vs $3.63) & FY guidance was increased on both revenues and EPS.
Jazz just presented data on JZP-258, it’s 90% low Xyrem that’s being developed for Nacrolepsy w Cataplexy attacks. Heading into the event there were a few key issues that we went over in our preview note.
This Wednesday at the 2019 World Sleep Congress (9/25/19) Jazz will present full data on JZP-258’s Ph3 withdrawal trial in adults with narcolepsy/cataplexy and hold a conference call immediately after, at 9PM EST.
Jazz recently acquired Cavion Inc for $52.5mm upfront and $260mm in clinical, regulatory and commercial milestone payments. This gives Jazz worldwide rights to CX-8998, which is being developed for essential tremor. Jazz plans to initiate an additional Ph.2b in 2020.
Jazz reported a decent Q219 earnings, beating on both the top ($534 vs $511mm) and bottom-line ($4.05 vs $3.61). The beat, yet again, was driven by Xyrem which came in ~$20mm higher than consensus estimates ($413 vs $392mm) while the rest of its portfolio came inline outside of Erwinaze which missed by $6mm due to ongoing supply issues with PBL which are well understood at this point. Vyxeos came inline vs consensus ($31 vs $32mm) driven by the ongoing EU launch.
Today (8/2/19) is the 1st of what we hope to make a reoccurring update of IMS charts we find interesting.
Jazz just reported a solid Q119 print, beating on both topline revs ($508 vs $468 cons.) and bottom-line EPS ( $3.67 vs $3.14) while also reaffirming its FY19 Guidance
Investors should be particularly pleased that Jazz’s largest product, Xyrem continues to beat consensus expectations ($368 vs $356 cons) while Vyxoes, its newly launched AML drug met consensus estimates of $29 mm for Q119.
- 1 of 2
- next →